AbbVie (NYSE:ABBV) Issues Q2 2025 Earnings Guidance

AbbVie (NYSE:ABBV - Get Free Report) updated its second quarter 2025 earnings guidance on Monday. The company provided earnings per share guidance of 2.840-2.880 for the period. The company issued revenue guidance of -. AbbVie also updated its FY 2025 guidance to 11.670-11.870 EPS.

AbbVie Price Performance

Shares of NYSE:ABBV traded down $0.22 during midday trading on Wednesday, hitting $189.55. 1,992,472 shares of the stock were exchanged, compared to its average volume of 7,034,063. AbbVie has a twelve month low of $163.81 and a twelve month high of $218.66. The stock has a market cap of $334.82 billion, a P/E ratio of 80.70, a PEG ratio of 1.25 and a beta of 0.48. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14. The company has a 50 day moving average price of $187.19 and a 200-day moving average price of $188.77.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. The company had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The firm's quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.31 EPS. On average, research analysts forecast that AbbVie will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a yield of 3.46%. The ex-dividend date of this dividend is Tuesday, July 15th. AbbVie's dividend payout ratio is currently 279.15%.

Wall Street Analyst Weigh In

Several brokerages recently commented on ABBV. Morgan Stanley raised their target price on AbbVie from $241.00 to $250.00 and gave the company an "overweight" rating in a report on Monday, April 28th. The Goldman Sachs Group reiterated a "neutral" rating and set a $194.00 target price on shares of AbbVie in a research note on Tuesday, April 8th. Guggenheim upped their target price on AbbVie from $214.00 to $216.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Wall Street Zen downgraded AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Finally, Bank of America boosted their target price on AbbVie to $204.00 and gave the stock a "hold" rating in a report on Monday, June 9th. Eight analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $211.29.

Institutional Investors Weigh In On AbbVie

A hedge fund recently raised its stake in AbbVie stock. Revolve Wealth Partners LLC grew its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 72.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,279 shares of the company's stock after acquiring an additional 3,064 shares during the period. Revolve Wealth Partners LLC's holdings in AbbVie were worth $1,294,000 at the end of the most recent reporting period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.